4D Molecular Therapeutics Enters Collaboration and License Agreement with Otsuka Pharmaceutical

On October 31, 2025, 4D Molecular Therapeutics, Inc. entered into a Collaboration and License Agreement with Otsuka Pharmaceutical Co., Ltd. The agreement grants Otsuka exclusive rights to develop and commercialize 4D-150 for ophthalmological diseases, including wet AMD and DME, in Japan, China, Australia, and other Asia-Pacific markets. Otsuka will lead regulatory and commercialization activities in these regions, while 4D Molecular Therapeutics will continue to lead global Phase 3 clinical activities. Otsuka will provide an upfront cash payment of $85 million and cost sharing of at least $50 million over the next three years. 4D Molecular Therapeutics is eligible for up to $335.5 million in potential milestone payments and tiered royalties based on net sales. The agreement includes provisions for termination, indemnities, and the establishment of a joint steering committee to oversee development and commercialization efforts.